London Daily

Focus on the big picture.
Tuesday, Jul 22, 2025

Coronavirus doctor's diary: Don't ask me which vaccine is best, please

Coronavirus doctor's diary: Don't ask me which vaccine is best, please

Dr John Wright of Bradford Royal Infirmary says he's noticed that his medical colleagues show a preference for one vaccine, while members of the public often prefer another. He argues that this isn't a time to be choosy.

The dash for vaccines has thrown up a rather peculiar situation. With so many pharmaceutical companies competing in this greatest of scientific races, we now have a variety of vaccines, and people are starting to ask me, "Do I get a choice?" And "Which vaccine would you recommend?"

The concept of consumer choice when it comes to immunisation, or even medications, is alien. No-one asks about the brand of their annual flu jab, or which company produces the MMR vaccine that will protect their precious children. But the intense global relief that greeted the Pfizer covid vaccine, and then Moderna, AstraZeneca and most recently Novavax and Janssen vaccines (though the last two are still awaiting regulatory approval) has created brand awareness in a population that has had a crash course in epidemiology and infectious diseases.

Elderly people wait for a Covid injection in Milan

My answer is a simple one: we take whatever vaccine we are given and thank the lucky Northern stars that we live in a developed country. The idea of choice seems so wrong, when there is such an acute shortage of vaccines across the world.

In Italy, however, it's reported that police unions are refusing the AstraZeneca vaccine in the belief that the Pfizer and Moderna vaccines are more effective, and some Italian doctors are said to be rejecting it on the grounds that it takes longer to provide immunity. It is still too early to make such claims: as evidence accumulates from the continuation of vaccine trials and real-world evidence we will get a clearer picture.

Comparing vaccines is not as simple as comparing cola drinks or cars. The clinical trials that have reported very early results will continue for their full 12-month duration and the results will become more reliable with time. We have yet to start vaccine trials that can make head-to-head comparisons between different vaccines, so it may be that early results reflect different populations, or dosing regimes.

Side-effects after the vaccines will also vary - some may cause localised problems such as sore arms, others systemic effects such as flu-like symptoms. Again, as vaccine roll-out continues we will get a better picture of these profiles.

Zimbabwe carried out its first Covid vaccinations on Friday, using the Sinopharm vaccine

In my very unscientific straw-polling of preferences I find my medical colleagues have a slight preference for the Pfizer vaccine - they tend to be more comfortable than non-medics with new mRNA technologies and preliminary trial data suggested better clinical effectiveness, which is a key part of all our clinical decision-making.

However when Pfizer's summary trial data was recently released by the US Food and Drug Administration it turned out that over 3,000 suspected but not confirmed cases of Covid were not included in the heavily publicised press releases, so the vaccine may well be less effective than the original 95% claim.

Front-line diary

Prof John Wright, a doctor and epidemiologist, is head of the Bradford Institute for Health Research, and a veteran of cholera, HIV and Ebola epidemics in sub-Saharan Africa. He is writing this diary for BBC News and recording from the hospital wards for BBC Radio.

In my patients and non-medical colleagues there seems to be a greater preference for the AZ vaccine. People are comforted by its made-in-Britain roots, and its more traditional, tried-and-tested viral vector platform, using a harmless virus to deliver the gene for the SARS-CoV-2 spike protein into the patient's body. The Johnson and Johnson vaccine (made by its subsidiary Janssen), takes the same approach.

The Novavax vaccine uses a novel nanoparticle technique - it consists of a laboratory-made SARS-CoV-2 spike protein together with an adjuvant, an agent that signals to the immune system that it must take defensive action. The UK has ordered 60 million doses, so Novavax is likely to be widely used as the roll-out continues.

There is a dismissive scepticism about Russian or Chinese alternatives both among doctors and members of the public, although the effectiveness of the rather scarily named Sputnik V looks pretty good and as yet unpublished results for Sinovac's CoronaVac, which have been circulating in the medical community, also look promising.

Sputnik I was a satellite, Sputnik V is a vaccine

I was due to have my hospital (Pfizer) vaccine just before Christmas, but the SARS-CoV-2 virus nipped in just beforehand and gave me a dose of the real thing. I have held out for a couple of months before re-joining the queue. It is likely that I will maintain a good immune response for the first two or three months, and I feel that while the vaccine is so precious, someone else will benefit more than me, so I would rather give up my dose to those in greater need. However having had possible reinfection already I don't want to push my luck by leaving it too long.

While being choosy about vaccines seems inappropriate to me, the reality is that some older health workers already have a choice and I will soon be in this position myself. My hospital is providing the Pfizer vaccine to all our staff. It will not be so long before my GP offers me the AZ vaccine or possibly the Novavax vaccine that I have been helping to trial, assuming it is licensed by then.

I would of course take any of these vaccines: they have all turned out to work much better than we could have imagined. If I had a choice then it would be an ethical decision. Which vaccine manufacturer reflects the zeitgeist of our collective humanity during the pandemic - the kindness and compassion, the sharing and donating?

I'm impressed by the companies that have offered to make doses available on a not-for-profit basis to low and middle-income countries. Others may have different ways to assess a company's ethics, but this is surely a time when we should encourage the pharmaceutical industry to show us what corporate social responsibility truly means.

Newsletter

Related Articles

0:00
0:00
Close
US Treasury Secretary Calls for Institutional Review of Federal Reserve Amid AI‑Driven Growth Expectations
UK Government Considers Dropping Demand for Apple Encryption Backdoor
Severe Flooding in South Korea Claims Lives Amid Ongoing Rescue Operations
Japanese Man Discovers Family Connection Through DNA Testing After Decades of Separation
Russia Signals Openness to Ukraine Peace Talks Amid Escalating Drone Warfare
Switzerland Implements Ban on Mammography Screening
Japanese Prime Minister Vows to Stay After Coalition Loses Upper House Majority
Pogacar Extends Dominance with Stage Fifteen Triumph at Tour de France
CEO Resigns Amid Controversy Over Relationship with HR Executive
Man Dies After Being Pulled Into MRI Machine Due to Metal Chain in New York Clinic
NVIDIA Achieves $4 Trillion Valuation Amid AI Demand
US Revokes Visas of Brazilian Corrupted Judges Amid Fake Bolsonaro Investigation
U.S. Congress Approves Rescissions Act Cutting Federal Funding for NPR and PBS
North Korea Restricts Foreign Tourist Access to New Seaside Resort
Brazil's Supreme Court Imposes Radical Restrictions on Former President Bolsonaro
Centrist Criticism of von der Leyen Resurfaces as she Survives EU Confidence Vote
Judge Criticizes DOJ Over Secrecy in Dropping Charges Against Gang Leader
Apple Closes $16.5 Billion Tax Dispute With Ireland
Von der Leyen Faces Setback Over €2 Trillion EU Budget Proposal
UK and Germany Collaborate on Global Military Equipment Sales
Trump Plans Over 10% Tariffs on African and Caribbean Nations
Flying Taxi CEO Reclaims Billionaire Status After Stock Surge
Epstein Files Deepen Republican Party Divide
Zuckerberg Faces $8 Billion Privacy Lawsuit From Meta Shareholders
FIFA Pressured to Rethink World Cup Calendar Due to Climate Change
SpaceX Nears $400 Billion Valuation With New Share Sale
Microsoft, US Lab to Use AI for Faster Nuclear Plant Licensing
Trump Walks Back Talk of Firing Fed Chair Jerome Powell
Zelensky Reshuffles Cabinet to Win Support at Home and in Washington
"Can You Hit Moscow?" Trump Asked Zelensky To Make Putin "Feel The Pain"
Irish Tech Worker Detained 100 days by US Authorities for Overstaying Visa
Dimon Warns on Fed Independence as Trump Administration Eyes Powell’s Succession
Church of England Removes 1991 Sexuality Guidelines from Clergy Selection
Superman Franchise Achieves Success with Latest Release
Hungary's Viktor Orban Rejects Agreements on Illegal Migration
Jeff Bezos Considers Purchasing Condé Nast as a Wedding Gift
Ghislaine Maxwell Says She’s Ready to Testify Before Congress on Epstein’s Criminal Empire
Bal des Pompiers: A Celebration of Community and Firefighter Culture in France
FBI Chief Kash Patel Denies Resignation Speculations Amid Epstein List Controversy
Air India Pilot’s Mental Health Records Under Scrutiny
Google Secures Windsurf AI Coding Team in $2.4 Billion Licence Deal
Jamie Dimon Warns Europe Is Losing Global Competitiveness and Flags Market Complacency
South African Police Minister Suspended Amid Organised Crime Allegations
Nvidia CEO Claims Chinese Military Reluctance to Use US AI Technology
Hong Kong Advances Digital Asset Strategy to Address Economic Challenges
Australia Rules Out Pre‑commitment of Troops, Reinforces Defence Posture Amid US‑China Tensions
Martha Wells Says Humanity Still Far from True Artificial Intelligence
Nvidia Becomes World’s First Four‑Trillion‑Dollar Company Amid AI Boom
U.S. Resumes Deportations to Third Countries After Supreme Court Ruling
Excavation Begins at Site of Mass Grave for Children at Former Irish Institution
×